Although potent antiretroviral therapy has reduced HIV related morbidity and mortality, concerns about treatment-related metabolic complications persist.1-4 These complications resemble metabolic and body composition abnormalities of the metabolic syndrome (MetSynd) described with increasing frequency in the general adult population.5,6 The MetSynd is clinically defined as having at least 3 of the following 5 conditions: impaired fasting glucose, increased waist circumference, elevated triglycerides, low high-density lipoprotein cholesterol (HDL-C), and hypertension.7 This constellation of metabolic and physical abnormalities is frequently associated with increased risk of insulin resistance and cardiovascular morbidity and mortality in the general population.7-11
There is considerable controversy about the completeness and precision of the current MetSynd definition and whether certain risk factors associated with proinflammatory states should be included in the definition.12,13 Despite this controversy, most agree that this constellation of risk factors predicts increased future risk of diabetes, cardiovascular events, and other complications.12-16 Current MetSynd criteria may therefore identify individuals who could benefit from lifestyle modification and in some cases pharmacologic interventions to delay the progression to diabetes and cardiovascular disease.
According to recent data from National Health and Nutrition Examination Survey III (NHANES III), the overall age-adjusted prevalence of MetSynd in adults increased from 29% to 32% over the last decade; women in the 20-39 age group experienced the most dramatic change, with MetSynd almost doubling in prevalence from 11% to 19%.17 In addition, data from NHANES III also indicate ethnic differences in the distribution of the syndrome; the highest prevalence was noted among Mexican American (36%) compared with white women (23%).18 This increase in MetSynd prevalence was largely ascribed to an increase in the prevalence of hypertriglyceridemia and high blood pressure. Other population-based studies of US adults have reported an association of high baseline body mass index (BMI), older age, and lack of alcohol intake with an increased risk for the MetSynd.19-21
There are limited data about the prevalence of the MetSynd among HIV-infected persons, but it seems to be higher than in the general population.22,23 Recent data from the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study, which does not include HIV negative participants, found that men were more likely than women to have MetSynd and that therapy with nonnucleoside reverse transcriptase inhibitors (NNRTIs) may be protective.24 Few studies have evaluated the risks and prevalence of MetSynd in the growing population of HIV-infected women. We, therefore, examined the prevalence of MetSynd among participants of the Women's Interagency HIV Study (WIHS) and assessed the association of MetSynd with HIV status, use of particular antiretroviral medications, and sociodemographic factors.
The WIHS is a prospective, multicenter cohort study of HIV-seropositive and high-risk HIV-seronegative women enrolled between October 1994 and November 1995 and between October 2001 and September 2002. Participants were recruited from community outreach and hospital-based programs in 6 inner-city sites (Bronx, NY; Brooklyn, NY; Washington, DC; Los Angeles, CA; San Francisco, CA; and Chicago, IL) and were evaluated every 6 months with standardized interviews and physical examination.25,26 Phlebotomy for determination of CD4 cell count, plasma HIV-1 RNA level, fasting glucose and lipids, and hepatitis C antibody status was also performed. Information about the use of all medications, including antihypertensives, antihyperglycemics, glucose-sensitizing agents, medications for dyslipidemias and antiretroviral agents, was recorded at each study visit. Highly active antiretroviral therapy (HAART) was defined as use of: (a) 2 or more nucleoside reverse transcriptase inhibitors (NRTIs) in combination with at least one protease inhibitor (PI) or one NNRTI; (b) 1 NRTI in combination with at least one PI and at least one NNRTI; (c) a regimen containing ritonavir and saquinavir in combination with one NRTI and no NNRTIs; or (d) an abacavir- or tenofovir-containing regimen of 3 or more NRTIs in the absence of both PIs and NNRTIs, except for the 3 NRTI regimens consisting of: abacavir + tenofovir + lamivudine or didanosine + tenofovir + lamivudine. Combinations of zidovudine (AZT) and stavudine (d4T) with either a PI or NNRTI were not considered HAART.
Informed consent was obtained from participants in accordance with procedures and consent materials reviewed and approved by the committee on human research at each of the collaborating institutions.
Definition of MetSynd
The primary endpoint of this cross-sectional study was prevalence of MetSynd at the index study visit. The recently updated National Cholesterol Education Program Adult Treatment Panel III definition was used to identify participants with the MetSynd.8 According to this definition, female participants who had 3 or more of the following criteria were considered to have MetSynd: (1) waist measurement ≥ 88 cm (≥35 in); (2) triglycerides of ≥150 mg/dL or drug treatment for elevated triglycerides; (3) HDL-C of <50 mg/dL or drug treatment for reduced HDL-C; (4) elevated blood pressure (systolic ≥130 mm Hg or diastolic ≥85 mm Hg, using the average of 2 seated measurements) or antihypertensive drug treatment; (5) fasting glucose ≥100 mg/dL or currently using antidiabetic medication.
Current alcohol use was defined as light (<3 drinks/wk), moderate (3-13 drinks/wk), or heavy (≥14 drinks/wk). Former alcohol use was not assessed. Menopausal status was reported at every visit and defined as the absence of menstruation for ≥12 months. Drug treatment for dyslipidemias [elevated triglyceride and/or low high-density lipoprotein (HDL)] was defined as use of fibrates and/or nicotinic acid.
The study period was from October 2000, when WIHS first began collecting fasting blood at study visits, to October 2004 (9 semiannual study visits). About 2393 women (1725 HIV infected and 668 HIV negative) with available fasting data and an assessment of MetSynd from at least one study visit were included in the analysis. Given available fasting data, less than 10% of waist measurement and blood pressure measurements were missing. Women fulfilling ≥3 criteria were considered to have MetSynd; women having ≤2 of the MetSynd criteria and no missing measures were considered not to have MetSynd. Women missing 1 or 2 MetSynd components were also considered not to have MetSynd if they fulfilled ≤1 or 0 of the remaining criteria, respectively. All other cases were excluded since, due to missing data, it was impossible to ascertain whether or not the person had MetSynd.
An index visit was defined as the participant's first visit with complete data on waist circumference, blood pressure, and fasting blood values during the study period. Fasting was defined as no oral intake except water or medication for at least 8 hours. Women could contribute more than once to the analysis, and in total, there were 7736 visits with complete data among the 2393 women; 2135 visits for HIV-negative and 5601 visits for HIV-infected women were included in the analysis.
The prevalence of MetSynd within each HIV serostatus group was compared in univariate analyses. Clinical and demographic predictors were assessed as follows: age, ethnicity/race, smoking, alcohol use, hepatitis C serostatus, and BMI. HIV-infected individuals were also analyzed according to antiretroviral use, CD4 cell counts, and HIV RNA plasma levels. Demographic characteristics were expressed as percentages within HIV serostatus groups and were compared by exact tests.
Robust covariance logistic regression models27 with repeated visits nested within study subjects were used to evaluate associations between MetSynd and covariates both overall and separately within HIV serostatus groups. Univariate modeling was initially performed to assess the contribution of HIV status, age, BMI, smoking, alcohol use, and other variables. Variables found significant in the univariate analyses were then fit simultaneously in multivariate models. Analyses were performed using SAS software (Version 9.0).
Demographic and clinical characteristics of the 2393 women in the study group are shown in Table 1. Thirty-five percent of all women were obese, with BMI >30 kg/m2. The HIV-uninfected women were younger (36 vs 40 years, P < 0.0001), more likely to drink (eg, 7% vs 3% heavy drinkers, P < 0.0001), more likely to smoke (71% vs 67% ever smoked, P < 0.011), and had fewer children than the HIV-infected women. The probability of hepatitis C seropositivity was higher among the seropositive than seronegative women (30% vs 18%, P < 0.0001). Overall, 3% of both HIV-infected and HIV-uninfected women were using an antidiabetic medication at the index visit.
Among the HIV-infected women, the mean CD4 cell count was 474 cells/μL and mean HIV-1 RNA plasma level was 3.1 log10 copies/mL. At the index visit, 18% of HIV-infected women were antiretroviral naive; 34% were on no antiretroviral medication, but not antiretroviral therapy naive, whereas 24% were taking PI-based HAART and 28% taking non-PI-based HAART therapy. Among women on antiretroviral therapy at the index visit, 15% were taking efavirenz; 24% taking stavudine; 14% taking nevirapine; and 15% taking PI/ritonavir, including 11% taking lopinavir/ritonavir and 5% taking atazanavir/ritonavir.
The prevalence of MetSynd was significantly higher among the HIV-infected than HIV-uninfected women (33% vs 22%, P < 0.0001) (Table 2). HIV-infected women had higher prevalence of elevated triglycerides (35% vs 16%, P < 0.0001), low HDL-C (63% vs 41%, P < 0.0001), and elevated blood pressure (32% vs 26%, P = 0.003). In HIV-infected compared with HIV-uninfected women, mean triglyceride level was higher (154 vs 101 mg/dL, P < 0.0001) and mean HDL-C was lower (46 vs 55 mg/dL, P < 0.0001). By contrast, the prevalence of abnormal waist circumference and elevated glucose was similar in the 2 groups, and there were no differences in mean fasting glucose or blood pressure measurements between HIV-infected and HIV-uninfected individuals (Table 2).
The prevalence of MetSynd among HIV-infected women varied by race and ethnicity (data not shown). MetSynd was less frequent among African American women (31%) than among white (42%) or Hispanic women (34%, P = 0.030). Of note, the use of particular antiretroviral agents did not differ significantly between HIV-seropositive African American compared with white and Hispanic women; among HIV-seropositive women, 11.6% of African American women used nelfinavir compared with 10.0% of white and Hispanic women (P = 0.62); 2.7% of African American compared with 4.5% of white and Hispanic women used atazanavir/ritonavir (P = 0.77); and 9.5% of African American compared with 12.4% of white and Hispanic women used lopinavir/ritonavir (P = 0.62). Although African American women had a lower prevalence of hypertriglyceridemia (27% vs 52% for white, P < 0.0001) and low HDL (58% vs 71%, for white P < 0.0001), they had higher prevalence of elevated blood pressure (38% vs 26% and 24% for white and Hispanic, respectively, P < 0.0001). There were no differences in prevalence of abnormal waist circumference or abnormal glucose by ethnic or racial category.
Figure 1 illustrates the number of HIV-uninfected and HIV-infected women with 0, 1, 2, and ≥3 features of the MetSynd. There were no significant differences in the proportion of HIV-seronegative and HIV-seropositive women with 1 or 2 components of the MetSynd; there were, however, differences by serostatus among women with 0 and ≥3 components of the MetSynd.
Table 3 displays the univariate and multivariate analyses performed separately in HIV-infected and HIV-uninfected women. In multivariate analyses restricted to HIV-infected women, factors significantly associated with MetSynd were white [odds ratio (OR) = 1.91, P < 0.001] or Hispanic (OR = 1.46, P = 0.0004) compared with African American ethnicity; older age (OR = 1.38 per 5 year increase, P < 0.0001); current smoking (OR = 1.31 vs never smoked, P = 0.014); higher BMI (OR = 2.05 for BMI 26-30 and OR = 5.72 for BMI >30 kg/m2 vs ≤21-25, P < 0.0001); and use of stavudine (OR = 1.28, P = 0.0092). Nevirapine use (OR = 0.75, P = 0.016) was protective as were light (OR = 0.86, P = 0.50) and moderate alcohol use (OR = 0.76, P = 0.017) compared with not using alcohol. There was a higher prevalence of MetSynd in women with HIV-1 RNA >50,000 copies/mL (OR = 1.36, P = 0.019). The use of ritonavir-boosted PIs was significantly associated with MetSynd in univariate (OR = 1.26, P = 0.002) but not multivariate analysis (OR = 1.15, P = 0.134). HAART use, with or without a PI, was not associated with MetSynd.
Among the HIV-seronegative women, older age, higher BMI, current smoking, and higher parity were significantly associated with MetSynd in multivariate models. There was no significant association of MetSynd with race/ethnicity among HIV-seronegative women.
HIV serostatus was independently and significantly associated with MetSynd in univariate (OR = 1.69, P < 0.0001) and multivariate analyses (OR = 1.79, P < 0.0001) with HIV-1-seropositive and HIV-1-seronegative women combined (Table 4). Other factors significantly associated with MetSynd in the multivariate analysis among all women in the study group included white and Hispanic race/ethnicity compared with African American (OR = 1.97, P < 0.0001 for white and OR = 1.42, P = 0.0002 for Hispanic); older age (OR = 1.38 per 5 year increase, P < 0.0001); and higher BMI (OR = 2.20 for BMI 26-30 and OR = 6.54 for BMI >30 kg/m2 vs ≤21-25, P < 0.0001). Hepatitis C infection was not associated with MetSynd in either serogroup in multivariate analysis.
In this study of more than 2000 HIV-infected and HIV-uninfected women, 1 of 3 HIV-infected women met the criteria for diagnosis of the MetSynd, a prevalence 50% higher than in the HIV-uninfected women. The specific components of MetSynd most influenced by HIV serostatus were presence of increased triglycerides and decreased HDL. Among the HIV-infected women, elevated HIV-1 RNA levels, stavudine use, white race, and Hispanic ethnicity were independently associated with the MetSynd. In addition, nevirapine and light to moderate alcohol use were protective. Although heavy alcohol use was not statistically protective, this could reflect the small number of persons in this group. In our cohort, older age was associated with the MetSynd, perhaps explained by increased prevalence of cholesterol and glucose abnormalities with age.28,29 We note that there were no significant differences in the proportion of HIV-infected and HIV-uninfected women with 1 or 2 components of the MetSynd. The prevalence of abnormal glucose (including diabetes) was very similar in the 2 serogroups. In addition, the prevalence of abnormal waist circumference in the HIV-seropositive women (42%) was nearly identical to that in the HIV-seronegative women (43%).30 This is similar to findings reported by others who noted that rates of central hypertrophy were comparable among HIV-seropositive and HIV-seronegative women. Our finding of similar prevalence of these 2 components in both serogroups suggests that they are important in the development of MetSynd and may be related to one another. In fact, a correlation between abdominal obesity and insulin resistance in HIV-seropositive and HIV-seronegative individuals has been well described by others31-33; although we did not assess insulin resistance, impaired fasting plasma glucose and diabetes are part of the same spectrum.8 Of note, and in contrast to recent studies, in the multivariate models, HAART or ritonavir-boosted PI use was not significantly associated with the MetSynd.34
Previous literature on MetSynd among HIV-1-seropositive persons reports an increased prevalence compared with seronegative controls. Most of the data, however, pertain to predominantly male cohorts. Estimates range from 17% to 45% depending on the population studied and definitions used.22,23,28,32,34-38 Palella et al,23 for example, reported a prevalence of 33% (OR = 1.43, P = 0.002) among HIV-infected men in the Multicenter AIDS Cohort Study compared with 27% among the HIV-negative controls, with increased waist circumference the most frequently occurring component in both HIV-infected and HIV-uninfected men. Among HIV-infected men, factors associated with MetSynd included older age and HAART use. In a cross-sectional study of 477 HIV-infected men and women from the Nutrition for Healthy Living (NFHL) study,39 the overall prevalence of MetSynd was 24%, lower than what was noted in our cohort. A recently published study by Mondy et al40 found a similar prevalence of the MetSynd among HIV-1-infected men and women from an urban Midwestern outpatient clinic and matched control subjects from the NHANES cohort. Potential explanations for the different findings may include differences in racial/ethnic characteristics or the higher rate of obesity (BMI > 30 kg/m2) among women in our study group or maybe a gender difference in the effect of HIV on MetSynd. In the NFHL study, women accounted for only 25% of the cohort. The most common metabolic abnormalities in the NFHL study were low HDL (prevalence 54%) and high triglycerides (prevalence 47%).
In our cohort, abnormal HDL and abnormal waist circumference were the most frequent components of the MetSynd, but the increased prevalence of MetSynd among HIV-infected women was primarily due to differences in abnormal lipid profiles. Whereas ethnicity and race were not predictive for MetSynd among HIV-negative women, we noted a protective effect of African American ethnicity among HIV-infected women, driven entirely by their higher HDL and lower triglyceride levels compared with white or Hispanic women. In our cohort, HIV-infected white and Hispanic women had a higher prevalence of abnormal HDL and triglycerides than did African American women. Similar trends have been reported in HIV-seronegative women: The NHANES III data, for example, report that African American women have higher HDL-C and lower triglyceride levels than white and Hispanic women.41 Of note, the use of particular antiretroviral agents did not differ significantly between African American compared with white or Hispanic women in our cohort. The observed ethnic/racial differences in MetSynd prevalence are therefore not explained by race-based differences in antiretroviral utilization patterns at the index visit.
Of note, diabetes was the least frequently occurring component of MetSynd in our HIV-infected women. It is, however, important to note that we did not assess for insulin resistance in our cohort and that diabetes occurs later in the spectrum of glucose intolerance and insulin resistance. The use of fasting glucose levels to diagnose glucose intolerance may underestimate the prevalence of insulin resistance. In our cohort, hepatitis C, previously associated with insulin resistance and/or diabetes,42 was not associated with MetSynd in either serogroup. As MetSynd itself predicts the development of diabetes in the general population,43 further study is needed to see whether this is among the HIV-seropositive populations, including those with HIV and hepatitis C virus coinfection.
A key question for patients and providers is the effect of antiretroviral therapy on MetSynd. In our cohort, stavudine was independently associated with the MetSynd. Our findings of an association of stavudine use with MetSynd extend those of Anastos et al44 who reported an association of stavudine use with higher triglyceride levels (166 vs 141 mg/dL among HIV-infected nonusers, P = 0.002) but not with any of the other measured lipids. We did not, however, find any associations between PI use and MetSynd. Furthermore, when we examined specific PIs, lopinavir/ritonavir, and atazanavir/ritonavir, we did not find any significant association with MetSynd. This is in contrast to several studies of mostly European men that have found an association of PIs with MetSynd,23,34,37,39 most likely due to its adverse effect on fasting glucose and triglycerides. Jacobson et al39 showed an increased risk of MetSynd among lopinavir/ritonavir users in the NFHL cohort. In a cross-sectional study of 710 HIV-infected patients from Spain, past (OR = 2.96, 95% confidence interval of 1.03 to 3.55) and current PI use (OR = 4.18, 95% confidence interval of 1.4 to 12.5) and stavudine use were associated with presence of MetSynd.34 Mondy et al,40 on the other hand, did not find differences between individuals with or without MetSynd with respect to type of antiretrovirals used, and protease use was associated only with higher triglyceride levels. It has been shown that PI has variable effect on the metabolic profile, such as, for example, an increase in HDL-C with nelfinavir45,46 and higher triglyceride levels with inclusion of ritonavir in the regimen,44 whereas stavudine has been shown to be associated with elevated triglycerides.44,47,48 These variable effects may be responsible for the lack of association between certain agents and the MetSynd, or there may be differences by sex or race in metabolic responses.
We did note, however, a protective effect of nevirapine, which has been previously described in the Multicenter AIDS Cohort Study.23 We postulated that this may be due to a previously described salutary effect of nevirapine on HDL-C49,50; in our cohort, prevalence of abnormal HDL was lower in nevirapine users compared with women not taking nevirapine (49.8% vs 65.5%, P < 0.0001). Interestingly, we also found that nevirapine users had a lower prevalence of abnormal glucose compared with women not on nevirapine (12.8% vs 18.4%, P = 0.036). This finding should be investigated further in other cohorts. Antiretroviral-naive status and PI-based or non-PI-based HAART were not predictive of the MetSynd in our cohort.
There are few data about the association of HIV-specific factors with the MetSynd, and the reports have been conflicting. Palella et al23 noted that men with a CD4 cell count <200 cells/μL were more likely to have the MetSynd, whereas Mondy et al36 reported that in a cohort of 472 predominantly male individuals, higher CD4 cell count was an independent predictor of MetSynd. Recent data from the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study cohort of over 10,000 HIV-infected individuals demonstrated that both CD4 cell count (OR 1.02 per 100 cells/μL increment) and HIV RNA (OR 1.04 per log10 increase) were associated with the MetSynd24; an association between higher risk of MetSynd and increasing viral loads was also reported by Jacobson et al.39 In our population of HIV-infected women, plasma HIV-1 RNA >50, 000 was associated with the MetSynd, whereas CD4 cell counts were not. It is possible that the chronic immune activation seen with untreated22,23 and treated24,25 HIV infection may explain the association of higher plasma HIV-1 RNA with the MetSynd,51 although data remain conflicting.39 HIV infection induces chronic immune activation52,53 and may thereby lead to a proinflammatory state, illustrated by increased levels of C-reactive protein, a marker of inflammation, in HIV-infected individuals.54,55 There are some data that this marker remains elevated despite potent and suppressive antiretroviral therapy56,57 and may be due to viral factors related to inflammation. The link between inflammation and diabetes, atherosclerosis, and the MetSynd has been well characterized in HIV-negative individuals.7,8,14,58-64 Further study is needed to determine whether a similar relationship exists among HIV-infected individuals and whether inflammation confers an additional risk factor in the development of MetSynd.
The strengths of our study rest in the fact that we report data for both HIV-infected and HIV-uninfected women from a large database of prospectively recorded variables required to define MetSynd. Moreover, the demographic profile of the WIHS cohort reflects the characteristics of HIV-infected women living in the United States, and these results are thus likely to be applicable to the general population of HIV-infected women in the United States. To our knowledge, this is the largest study evaluating the prevalence and risk factors of this syndrome among HIV-1-infected women, with the additional advantage of an HIV-negative comparison group.
Limitations of the study include the cross-sectional design that precludes inferences about causality. Longitudinal follow-up data can further elucidate associations of MetSynd with particular antiretroviral regimens and characteristics of HIV disease.
In conclusion, our study demonstrates that 33% of HIV-infected women meet criteria for diagnosis of MetSynd, a prevalence which is 50% higher than that seen in HIV-negative comparators, mainly due to an increased prevalence of high triglyceride and low HDL levels among the HIV infected. We also identify strong associations between the MetSynd and HIV viral load itself and between MetSynd and BMI, age, smoking status, and specific antiretroviral agents. These findings have implications for the care of HIV-infected women in terms of decisions regarding antiretroviral therapy and the importance of early interventions to modify lifestyle factors that may lead to development of abnormal lipid profiles. Further studies are needed to examine the incidence of the MetSynd over time and to elucidate the role of inflammation and its association with the MetSynd in this population.
1. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med
2. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol
3. Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother
4. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women
. J Acquir Immune Defic Syndr
5. Carr A, Samaras K, Chisholm DJ, et al. Abnormal fat distribution and use of protease inhibitors. Lancet
6. Barbaro G, Barbarini G. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk. Chemotherapy
7. Grundy SM, Brewer HB Jr., Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation
8. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation
9. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation
10. Zimmet P, Magliano D, Matsuzawa Y, et al. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb
11. Grundy SM, Bazzarre T, Cleeman J, et al. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation
12. Magliano DJ, Shaw JE, Zimmet PZ. How to best define the metabolic syndrome. Ann Med
13. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet
14. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia
15. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women
16. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation
17. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care
18. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA
19. Carnethon MR, Loria CM, Hill JO, et al. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care
20. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med
21. Zhu S, St-Onge MP, Heshka S, et al. Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism
22. Gazzaruso C, Sacchi P, Garzaniti A, et al. Prevalence of metabolic syndrome among HIV patients. Diabetes Care
23. Palella F, Wang Z, Chu H, et al. Correlates of the metabolic syndrome among HIV seropositive and seronegative men in the Multicenter AIDS Cohort Study. Paper presented at: Conference of Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO.
24. Worm S, Sabin C, El-Sadr W, et al. The Metabolic Syndrome at baseline in the D:A:D study. Paper presented at: 8th International Congress on Drug Therapy in HIV Infection; Poster P124; November 12-16, 2006; Glasgow, Scotland.
25. Bacon MC, von Wyl V, Alden C, et al. The Women
's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol
26. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women
's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology
27. Diggle P, Heagerty P, Liang KY, et al. Analysis of Longitudinal Data
. Oxford, England: Oxford Science Publication; 1994.
28. Bonfanti P, Giannattasio C, Ricci E, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr
29. Mancia G, Facchetti R, Bombelli M, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension
30. Tien PC, Stephen RC, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the Women
's Interagency HIV Study. J Acquir Immune Defic Syndr
31. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab
32. Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis
33. Jensen MD, Haymond MW, Rizza RA, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest
34. Jerico C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care
35. Bruno R, Gazzaruso C, Sacchi P, et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr
36. Mondy K, Tong S, Kessels L, et al. Metabolic Syndrome in HIV Within a Representative U.S. Population
. Denver, CO: CROI; 2006.
37. Bergersen BM, Schumacher A, Sandvik L, et al. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis
38. Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and (corrected) hypoadiponectinemia. Diabetes Care
39. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr
40. Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis
41. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA
42. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr
43. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care
44. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr
45. Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab
46. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr
47. van Leth F, Hall DB, Lange JM, et al. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med
48. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA
49. Bergersen BM, Tonstad S, Sandvik L, et al. Low prevalence of high-density lipoprotein cholesterol level <1 mmol/L in non-nucleoside reverse transcriptase inhibitor recipients. Int J STD AIDS
50. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther
51. Mangili A, Jacobson D, Gerrior J, et al. Metabolic syndrome and markers of early atherosclerosis in a cohort of HIV-infected subjects from nutrition for healthy living. Paper presented at: CROI; February 22-25, 2005; Boston, MA.
52. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood
53. Liu Z, Cumberland WG, Hultin LE, et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol
54. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women
. J Acquir Immune Defic Syndr
55. Feldman JG, Goldwasser P, Holman S, et al. C-reactive protein is an independent predictor of mortality in women
with HIV-1 infection. J Acquir Immune Defic Syndr
56. Henry K, Kitch D, Dube M, et al. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS
57. Sklar P, BW, Csako G, et al. C-reactive protein may be an important biomarker of cardiovascular risk and does not appear to be confounded by antiretroviral use or HIV viremia. Paper presented at: CROI; February 10-14, 2003; Boston, MA.
58. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation
59. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care
60. Florez H, Castillo-Florez S, Mendez A, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract
61. Florez H, Silva E, Fernandez V, et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract
62. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis
63. McNeill AM, Rosamond WD, Girman CJ, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol
64. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA